Evidence map›Paper›PMID 41016994›Full record

ArticleAIDS and behavior2026

Differences in Methamphetamine Use, Self-Reported Impact, and HIV-Related Outcomes by Gender and Sexual Orientation in a Multisite U.S. Cohort of People with HIV in Care.

R J Fredericksen, R M Nance, L N Drumright, L S Mixson, S A Ruderman, B M Whitney, C Fahey, K H Mayer, J P Jain, M Saag and 12 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

R J FredericksenDepartment of Medicine, University of Washington, Seattle, WA, USA. rfrederi@uw.edu.
R M NanceDepartment of Medicine, University of Washington, Seattle, WA, USA.
L N DrumrightDepartment of Medicine, University of Washington, Seattle, WA, USA.
L S MixsonDepartment of Medicine, University of Washington, Seattle, WA, USA.
S A RudermanDepartment of Medicine, University of Washington, Seattle, WA, USA.
B M WhitneyDepartment of Medicine, University of Washington, Seattle, WA, USA.
C FaheyDepartment of Medicine, University of Washington, Seattle, WA, USA.
K H MayerFenway Institute, Boston, MA, USA.
J P JainDepartment of Medicine, University of California-San Francisco, San Francisco, CA, USA.
M SaagDepartment of Medicine, University of Alabama-Birmingham, Birmingham, AL, USA.
J EronUniversity of North Carolina, Chapel Hill, NC, USA.
S NapravnikUniversity of North Carolina, Chapel Hill, NC, USA.
L BamfordUniversity of California, San Diego, CA, USA.
E CachayUniversity of California, San Diego, CA, USA.
G A YendewaCase Western Reserve University, Cleveland, OH, USA.
J KerulyJohns Hopkins University, Baltimore, MD, USA.
R D MooreJohns Hopkins University, Baltimore, MD, USA.
A RodriguezUniversity of Miami, Miami, FL, USA.
S SafrenUniversity of Miami, Miami, FL, USA.
J A C DelaneyDepartment of Medicine, University of Washington, Seattle, WA, USA.
H M CraneDepartment of Medicine, University of Washington, Seattle, WA, USA.
A W HahnDepartment of Medicine, University of Washington, Seattle, WA, USA.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 1988 to 2026
$84.1M
Substance use patterns and contexts: impact on epigenetic age and prevention strategies in an HIV clinical care cohortR01DA047045 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Joseph Austin Delaney · 2018 to 2026
$5.1M
HIV and Substance Use Cohort Coordinating Center for Emerging and High Impact Scientific Cross Cohort Studies: HIV SUCCESSU24DA058307 · NIDA · UNIVERSITY OF WASHINGTON · PI GEETANJALI CHANDER, Heidi M. Crane · 2023 to 2026
$3.6M
Understanding Health Inequities at the Intersection of the HIV and substance use epidemics across racial/ethnic and other underserved populationsR01DA058938 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Rob Fredericksen · 2023 to 2026
$2.8M
Women, Intersectionality, Substance Use and HIV ( WISH)K01DA056306 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Payaal Jain · 2022 to 2026
$1.0M
NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027767NIAID NIH HHS R24 AI067039NIDA NIH HHS K01 DA056306NIDA NIH HHS R01 DA047045NIDA NIH HHS R01DA047045NIDA NIH HHS R01 DA058938NIDA NIH HHS R01DA058938NIDA NIH HHS U24 DA058307NIDA NIH HHS U24DA058307
6 · The paper itself

Abstract

We aimed to identify methamphetamine use patterns and impact by gender/sexual orientation among people with HIV (PWH) in care. We queried 3-month drug use/impact. Women were grouped by gender (cis/trans); cisgender men by sexual orientation. Differences in drug use/impact were assessed using chi-squared and t-tests. We used linear and logistic regression models for each drug use measure, adjusting for age and race/ethnicity. Among 13938 PWH (MA 48), 30% reported ever using methamphetamine; 10% reported current use; 79% were cisgender men (74% men who have sex with men (MSM), 20% men who have sex with women (MSW), 6% men who have sex with men/women (MSMW). Among women (21%), 8% were transgender (TW). TW and MSM reported higher current methamphetamine use (each 14%) than other groups [MSMW (13%), MSW (6%), CW (3%)(p < 0.001)]. Severity of use was highest among TW, compared to MSM (17.8 vs. 14.1, p = 0.04). All groups using methamphetamine were more likely than MSM to currently use cocaine/crack (p = 0.002-0.04); all but TW were more likely than MSM to report illicit opioid use (p < 0.001-0.03). MSM had highest injection use (34% vs. 17-25%, p = 0.05). Related health/legal/financial/social problems were most frequent among TW and MSMW (71%, 55%)]. Persons currently using methamphetamine had lower antiretroviral adherence than those not using (81-85% vs. 91-94%), and higher detectable viral load (28-41% vs. 13-20%). In the adjusted analysis, TW were more likely than MSM to report daily/almost daily use (p = 0.04). Methamphetamine use and impact differ by gender and by cisgender men's sexual orientation, warranting inquiry into moderating factors.

Indexed as

Amphetamine-Related DisordersHIV InfectionsMethamphetamineSexual BehaviorAdultCohort StudiesFemaleHomosexuality, MaleHumansMaleMiddle AgedSelf ReportSex FactorsSexual and Gender MinoritiesSubstance-Related DisordersUnited StatesMethamphetamineMethamphetamine usePeople with HIVSubstance use

Identifiers

PMID41016994
PMCPMC12970557

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.